Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors

Biochemical and Biophysical Research Communications

Volumn 478, Issue 1, 2016, Pages 227-233

  Zou, Zhengzhi ^a   Luo, Xiaoyong ^b   Nie, Peipei ^c   Wu, Baoyan ^a   Zhang, Tao ^a   Wei, Yanchun ^a   Wang, Wenyi ^d   Geng, Guojun ^d   Jiang, Jie ^d   Mi, Yanjun ^d  

^a SOUTH CHINA NORMAL UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

AKT; Apoptosis; Bcl 2; Cancer; HDAC; SRC 3

Indexed keywords

BUFALIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; ROMIDEPSIN; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 3; SUBERANILOHYDROXAMIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DEPSIPEPTIDE; NCOA3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; PRIORITY JOURNAL; A-549 CELL LINE; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; GENE SILENCING; GENETICS; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR CELL LINE;

A549 CELLS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS, EXPERIMENTAL; NUCLEAR RECEPTOR COACTIVATOR 3;

EID: 84978792908     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.07.063     Document Type: Article

References (38)

1. [1] Coste, A., Antal, M.C., Chan, S., Kastner, P., Mark, M., O'Malley, B.W., Auwerx, J., Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J. 25 (2006), 2453–2464.
2. [2] Yan, J., Erdem, H., Li, R., Cai, Y., Ayala, G., Ittmann, M., Yu-Lee, L.Y., Tsai, S.Y., Tsai, M.J., Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 68 (2008), 5460–5468.
3. [3] Tien, J.C., Xu, J., Steroid receptor coactivator-3 as a potential molecular target for cancer therapy. Expert Opin. Ther. Targets 16 (2012), 1085–1096.
4. [4] Gojis, O., Rudraraju, B., Gudi, M., Hogben, K., Sousha, S., Coombes, R.C., Cleator, S., Palmieri, C., The role of SRC-3 in human breast cancer. Nat. Rev. Clin. Oncol. 7 (2010), 83–89.
5. [5] Lahusen, T., Henke, R.T., Kagan, B.L., Wellstein, A., Riegel, A.T., The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res. Treat. 116 (2009), 225–237.
6. [6] Palmieri, C., Gojis, O., Rudraraju, B., Stamp-Vincent, C., Wilson, D., Langdon, S., Gourley, C., Faratian, D., Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br. J. Cancer 108 (2013), 2039–2044.
7. [7] Burandt, E., Jens, G., Holst, F., Janicke, F., Muller, V., Quaas, A., Choschzick, M., Wilczak, W., Terracciano, L., Simon, R., Sauter, G., Lebeau, A., Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. Breast Cancer Res. Treat. 137 (2013), 745–753.
8. [8] Nakles, R.E., Shiffert, M.T., Diaz-Cruz, E.S., Cabrera, M.C., Alotaiby, M., Miermont, A.M., Riegel, A.T., Furth, P.A., Altered AIB1 or AIB1Delta3 expression impacts ERalpha effects on mammary gland stromal and epithelial content. Mol. Endocrinol. 25 (2011), 549–563.
9. [9] Mussi, P., Yu, C., O'Malley, B.W., Xu, J., Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol. Endocrinol. 20 (2006), 3105–3119.
10. [10] Aumann, S., Abdel-Wahab, O., Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochem. Biophys. Res. Commun. 455 (2014), 24–34.
11. [11] Dhanak, D., Jackson, P., Development and classes of epigenetic drugs for cancer. Biochem. Biophys. Res. Commun. 455 (2014), 58–69.
12. [12] Lou, Y.F., Zou, Z.Z., Chen, P.J., Huang, G.B., Li, B., Zheng, D.Q., Yu, X.R., Luo, X.Y., Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One, 9, 2014, e97719.
13. [13] Liu, J., Edagawa, M., Goshima, H., Inoue, M., Yagita, H., Liu, Z., Kitajima, S., Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells. Biochem. Biophys. Res. Commun. 445 (2014), 320–326.
14. [14] Xu, W., Xu, B., Yao, Y., Yu, X., Shen, J., The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production. Biochem. Biophys. Res. Commun. 463 (2015), 545–550.
15. [15] Jones, P.A., Baylin, S.B., The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002), 415–428.
16. [16] Yang, D., Torres, C.M., Bardhan, K., Zimmerman, M., McGaha, T.L., Liu, K., Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J. Immunol. 188 (2012), 4441–4449.
17. [17] Liu, Y., Tong, Z., Li, T., Chen, Q., Zhuo, L., Li, W., Wu, R.C., Yu, C., Hepatitis B virus X protein stabilizes amplified in breast cancer 1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness. Hepatology 56 (2012), 1015–1024.
18. [18] Wu, M.Y., Fu, J., Xu, J., O'Malley, B.W., Wu, R.C., Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor. Cell Res. 22 (2012), 1003–1021.
19. [19] Zou, Z., Yuan, Z., Zhang, Q., Long, Z., Chen, J., Tang, Z., Zhu, Y., Chen, S., Xu, J., Yan, M., Wang, J., Liu, Q., Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 8 (2012), 1798–1810.
20. [20] Zou, Z.Z., Nie, P.P., Li, Y.W., Hou, B.X., Rui-Li, Shi, X.P., Ma, Z.K., Han, B.W., Luo, X.Y., Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget, 2015, 10.18632/oncotarget.5628 [Epub ahead of print].
21. [21] Nie, P., Hu, W., Zhang, T., Yang, Y., Hou, B., Zou, Z., Synergistic induction of Erlotinib-mediated apoptosis by resveratrol in human non-small-cell lung cancer cells by down-regulating survivin and up-regulating PUMA. Cell. Physiol. Biochem. 35 (2015), 2255–2271.
22. [22] Luo, X., Yao, J., Nie, P., Yang, Z., Feng, H., Chen, P., Shi, X., Zou, Z., FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation. Oncotarget, 2016, 10.18632/oncotarget.8419 [Epub ahead of print].
23. [23] Wang, Y., Lonard, D.M., Yu, Y., Chow, D.C., Palzkill, T.G., Wang, J., Qi, R., Matzuk, A.J., Song, X., Madoux, F., Hodder, P., Chase, P., Griffin, P.R., Zhou, S., Liao, L., Xu, J., O'Malley, B.W., Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 74 (2014), 1506–1517.
24. [24] Jiang, S., Zou, Z., Nie, P., Wen, R., Xiao, Y., Tang, J., Synergistic effects between mTOR complex 1/2 and glycolysis inhibitors in non-small-cell lung carcinoma cells. PLoS One, 10, 2015, e0132880.
25. [25] Mottamal, M., Zheng, S., Huang, T.L., Wang, G., Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20 (2015), 3898–3941.
26. [26] Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R., FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007), 1247–1252.
27. [27] Shi, W., Lawrence, Y.R., Choy, H., Werner-Wasik, M., Andrews, D.W., Evans, J.J., Judy, K.D., Farrell, C.J., Moshel, Y., Berger, A.C., Bar-Ad, V., Dicker, A.P., Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. J. Neurooncol. 118 (2014), 313–319.
28. [28] Sarfstein, R., Bruchim, I., Fishman, A., Werner, H., The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One, 6, 2011, e24468.
29. [29] Yi, P., Xia, W., Wu, R.C., Lonard, D.M., Hung, M.C., O'Malley, B.W., SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev. 27 (2013), 274–287.
30. [30] Cai, D., Shames, D.S., Raso, M.G., Xie, Y., Kim, Y.H., Pollack, J.R., Girard, L., Sullivan, J.P., Gao, B., Peyton, M., Nanjundan, M., Byers, L., Heymach, J., Mills, G., Gazdar, A.F., Wistuba, I., Kodadek, T., Minna, J.D., Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 70 (2010), 6477–6485.
31. [31] Xu, Y., Chen, Q., Li, W., Su, X., Chen, T., Liu, Y., Zhao, Y., Yu, C., Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. Oncogene 29 (2010), 3386–3397.
32. [32] Carlisi, D., Lauricella, M., D'Anneo, A., Buttitta, G., Emanuele, S., di Fiore, R., Martinez, R., Rolfo, C., Vento, R., Tesoriere, G., The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells. J. Cell. Physiol. 230 (2015), 1276–1289.
33. [33] Zhang, P., Guo, Z., Wu, Y., Hu, R., Du, J., He, X., Jiao, X., Zhu, X., Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling. PLoS One, 10, 2015, e0136193.
34. [34] Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., Peng, T.I., Jones, D.P., Wang, X., Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997), 1129–1132.
35. [35] Colo, G.P., Rosato, R.R., Grant, S., Costas, M.A., RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett. 581 (2007), 5075–5081.
36. [36] Zhou, H.J., Yan, J., Luo, W., Ayala, G., Lin, S.H., Erdem, H., Ittmann, M., Tsai, S.Y., Tsai, M.J., SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65 (2005), 7976–7983.
37. [37] Xu, W., Ngo, L., Perez, G., Dokmanovic, M., Marks, P.A., Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 15540–15545.
38. [38] Bali, P., Pranpat, M., Swaby, R., Fiskus, W., Yamaguchi, H., Balasis, M., Rocha, K., Wang, H.G., Richon, V., Bhalla, K., Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res. 11 (2005), 6382–6389.